[1] Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes[J]. Br J Surg, 2013,100(8):1009-1014. DOI: 10.1002/bjs.9192.
[2] Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines[J]. BMJ, 2001,323(7308):334-336. DOI: 10.1136/bmj.323.7308.334.
[3] Miner TJ, Jaques DP, Paty PB, et al. Symptom control in patients with locally recurrent rectal cancer[J]. Ann Surg Oncol, 2003,10(1):72-79. DOI: 10.1245/aso.2003.03.040.
[4] Malcolm FL, Adiamah A, Banerjea A, et al. Long-term health-related quality of life following colorectal cancer surgery: patient-reported outcomes in a remote follow- up population[J]. Colorectal Dis, 2021,23(1):213-225. DOI: 10.1111/codi.15393.
[5] Nolte S, Liegl G, Petersen MA, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States[J]. Eur J Cancer, 2019,107:153-163. DOI: 10.1016/j.ejca.2018.11.024.
[6] Mizukami Y, Ueda S, Mizumoto A, et al. Diffusion- weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer[J]. World J Surg, 2011,35(4):895-899. DOI: 10.1007/s00268-011-0986-x.
[7] 中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会结直肠肿瘤专业委员会腹腔镜专业委员会,中华医学会外科学分会结直肠外科学组.中国直肠癌侧方淋巴结转移诊疗专家共识(2019版)[J].中华胃肠外科杂志, 2019, 22 (10):901-912. DOI:10.3760/cma.j.issn.1671-0274.2019. 10.001.
[8] Lu YY, Chen JH, Chien CR, et al. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis[J]. Int J Colorectal Dis, 2013,28(8):1039-1047. DOI: 10.1007/s00384-013-1659-z.
[9] Kau T, Reinprecht P, Eicher W, et al. FDG PET/CT in the detection of recurrent rectal cancer[J]. Int Surg, 2009,94(4):315-324. DOI: 10.1007/s00259-006-0072-z
[10] Watson AJ, Lolohea S, Robertson GM, et al. The role of positron emission tomography in the management of recurrent colorectal cancer: a review[J]. Dis Colon Rectum, 2007,50(1): 102-114. DOI: 10.1007/s10350-006-0735-7.
[11] Plodeck V, Rahbari NN, Weitz J, et al. FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences[J]. Eur Radiol, 2019,29(1):422-428. DOI: 10.1007/s 00330-018-5589-6.
[12] Matsuyama T, Yamauchi S, Masuda T, et al. Treatment and subsequent prognosis in locally recurrent rectal cancer: a multicenter retrospective study of 498 patients[J]. Int J Colorectal Dis, 2021,36(6):1243-1250. DOI: 10.1007/s00384-021-03856-3.
[13] 裴炜, 熊斌, 崔书中, 等. 结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识(V2019)[J/CD]. 中华结直肠疾病电子杂志,2019,8(4):329-335.DOI:10.3877/cma.j.issn.2095- 3224.2019.04.002.
[14] Boyle KM, Sagar PM, Chalmers AG, et al. Surgery for locally recurrent rectal cancer[J]. Dis Colon Rectum, 2005,48(5):929-937. DOI: 10.1007/s10350-004-0909-0.
[15] Moore HG, Shoup M, Riedel E, et al. Colorectal cancer pelvic recurrences: determinants of resectability[J]. Dis Colon Rectum, 2004,47(10):1599-1606. DOI: 10.1007/s10350-004-0677-x.
[16] 张峻岭,吴涛,陈国卫,等.局部复发直肠癌手术根治性和预后的影响因素分析[J].中华胃肠外科杂志,2020,23(5):472-479. DOI:10.3760/cma.j.cn.441530-20200207-00042.
[17] 郭鹏,王畅,杨晓东,等.直肠癌骶前复发不同手术方式的临床疗效比较[J].中华胃肠外科杂志, 2020,23(5):466-471. DOI:10.3760/cma.j.cn.441530-20200210-00045.
[18] 中国医师协会外科医师分会结直肠外科医师委员会,中国医师协会结直肠肿瘤专业委员会器官功能保护专业委员会,中国医师协会肛肠医师分会,等. 直肠癌骶前复发诊疗专家共识[J]. 中华胃肠外科杂,2020,23(5):438-444.DOI:10.3760/cma.j.cn.441530-20200303-00110.
[19] Li Y, Wang J, Ma X, et al. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Int J Biol Sci, 2016,12(8):1022-1031. DOI: 10.7150/ijbs. 15438.
[20] Kong JC, Soucisse M, Michael M, et al. Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and meta-analysis of oncological and operative outcomes[J]. Ann Surg Oncol, 2021,28(12):7476-7486. DOI: 10.1245/s10434-021-09837-8.
[21] Denost Q, Frison E, Salut C, et al. A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer-GRECCAR 15 trial protocol[J]. Colorectal Dis, 2021,23(7):1909-1918. DOI: 10.1111/codi.15670.
[22] PelvEx Collaborative. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II)[J]. BJS Open, 2021,5(3):zrab029. DOI: 10.1093/bjsopen/zrab029.
[23] Fahy MR, Kelly ME, Power Foley M, et al. The role of intraoperative radiotherapy in advanced rectal cancer: a meta-analysis[J]. Colorectal Dis, 2021,23(8):1998-2006. DOI: 10.1111/codi. 15698.
[24] Cameron MG, Kersten C, Vistad I, et al. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer-a systematic review[J]. Acta Oncol, 2014,53(2):164-173. DOI: 10.3109/ 0284186X. 2013.837582.
[25] Dijkstra EA, Mul V, Hemmer P, et al. Re-Irradiation in patients with recurrent rectal cancer is safe and feasible[J]. Ann Surg Oncol, 2021,28(9):5194-5204. DOI: 10.1245/s10434-021- 10070-6.
[26] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)结直肠癌诊疗指南2022[M]. 北京: 人民卫生出版社, 2022.
[27] Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer[J]. N Engl J Med, 2022,386(25):2363-2376. DOI: 10.1056/NEJMoa 2201445.
[28] Yang TX, Morris DL, Chua TC. Pelvic exenteration for rectal cancer: a systematic review[J]. Dis Colon Rectum, 2013,56(4):519-531. DOI: 10.1097/DCR.0b013e31827a7868.
[29] Lee DJ, Sagar PM, Sadadcharam G, et al. Advances in surgical management for locally recurrent rectal cancer: How far have we come?[J]. World J Gastroenterol, 2017,23(23):4170- 4180. DOI: 10.3748/wjg.v23.i23.4170.
[30] Dozois EJ, Privitera A, Holubar SD, et al. High sacrectomy for locally recurrent rectal cancer: Can long-term survival be achieved?[J]. J Surg Oncol, 2011,103(2):105-109. DOI: 10.1002/jso.21774.
[31] PelvEx Collaborative. Minimally invasive surgery techniques in pelvic exenteration: a systematic and meta-analysis review[J]. Surg Endosc, 2018,32(12):4707-4715. DOI: 10.1007/s00464-018-6299-5.
[32] Sun Y, Yang H, Zhang Z, et al. Fascial space priority approach for laparoscopic total pelvic exenteration in patients with locally advanced rectal cancer[J]. Surg Endosc, 2022,36(8):6331-6335. DOI:10.1007/s00464- 022-09216-8.
[33] Kazi M, Kumar N, Rohila J, et al. Minimally invasive versus open pelvic exenterations for rectal cancer: a comparative analysis of perioperative and 3-year oncological outcomes[J]. BJS Open, 2021,5(5). DOI: 10.1093/bjsopen/zrab074.
[34] Tang J, Liu J, Du B, et al. Short- and long-term outcomes of laparoscopic versus open pelvic exenteration for locally advanced rectal cancer: a single-center propensity score matching analysis[J]. Tech Coloproctol, 2022. DOI: 10. 1007/s10151-022-02691-0.
[35] 左帅, 陈贺凯, 郑利军, 等. 腹腔镜后盆腔脏器切除术治疗局部进展期直肠癌临床效果分析[J]. 结直肠肛门外科, 2020,26(2):148-153. DOI: 10.19668/j.cnki.issn1674- 0491. 2020.02.007.
[36] Yang K, Cai L, Yao L, et al. Laparoscopic total pelvic exenteration for pelvic malignancies: the technique and short-time outcome of 11 cases[J]. World J Surg Oncol, 2015,13:301. DOI: 10.1186/s12957-015-0715-2.
[37] Nagasaki T, Akiyoshi T, Ueno M, et al. Laparoscopic salvage surgery for locally recurrent rectal cancer[J]. J Gastrointest Surg, 2014,18(7):1319-1326. DOI: 10.1007/s11605-014-2537-x.
[38] PelvEx Collaborative. Palliative pelvic exenteration: a systematic review of patient-centered outcomes[J]. Eur J Surg Oncol, 2019,45(10):1787-1795. DOI: 10.1016/j.ejso.2019.06.011.
[39] Chen YG, Liu YL, Jiang SX, et al. Adhesion pattern and prognosis studies of T4N0M0 colorectal cancer following en bloc multivisceral resection: evaluation of T4 subclassification[J]. Cell Biochem Biophys, 2011,59(1):1-6. DOI: 10.1007/s12013-010-9106-z.
[40] 王锡山. 结直肠癌联合脏器切除得与失及临床病理分期的思考[J].中国实用外科杂志, 2010,30(12):1002-1004.
[41] 陈瑛罡, 刘彦龙, 刘正, 等. 原发ⅡC期结直肠癌患者炎性浸润与癌性浸润预后的比较研究[J]. 中华胃肠外科杂志, 2011,14(4):267-270. DOI: 10.3760/cma.j.issn.1671-0274.2011. 04.011.
[42] Kazi M, Rohila J, Kumar NA, et al. Urinary reconstruction following total pelvic exenteration for locally advanced rectal cancer: complications and factors affecting outcomes[J]. Langenbecks Arch Surg, 2021,406(2):329- 337. DOI: 10.1007/s00423-021-02086-z.
[43] Johnson YL, West MA, Gould LE, et al. Empty pelvis syndrome: a systematic review of reconstruction techniques and their associated complications[J]. Colorectal Dis, 2022,24(1):16-26. DOI: 10.1111/codi.15956.
[44] 程文悦, 杨旭霞, 陈思诗, 等. 不同组织来源生物补片降解性能的比较研究[J/CD].中华疝和腹壁外科杂志(电子版), 2021,15(1):97-101. DOI:10.3877/cma.j.issn.1674-392X. 2021.01.023.
[45] 谢昆, 温冰, 翟伟, 等. 穿支皮瓣在修复会阴区肿瘤术后缺损中的应用[J].中华整形外科杂志, 2018, 34(9):704-708. DOI:10.3760/cma.j.issn.1009-4598.2018.09.005.
[46] Bogner A, Fritzmann J, Müssle B, et al. Pelvic exenteration for colorectal and non-colorectal cancer: a comparison of perioperative and oncological outcome[J]. Int J Colorectal Dis, 2021,36(8):1701-1710. DOI: 10.1007/s00384-021- 03893-y.
[47] Rausa E, Kelly ME, Bonavina L, et al. A systematic review examining quality of life following pelvic exenteration for locally advanced and recurrent rectal cancer[J]. Colorectal Dis, 2017,19(5):430-436. DOI: 10.1111/codi.13647.
[48] Konstantinidis IT, Lee B, Trisal V, et al. National postoperative and oncologic outcomes after pelvic exenteration for T4b rectal cancer[J]. J Surg Oncol, 2020.DOI: 10.1002/jso.26058.
[49] PelvEx Collaborative. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration[J]. Ann Surg, 2019,269(2):315-321. DOI: 10.1097/SLA.0000000000002528.
[50] Moghadamyeghaneh Z, Hwang GS, Hanna MH, et al. Surgical site infection impact of pelvic exenteration procedure[J]. J Surg Oncol, 2015,112(5):533-537. DOI: 10. 1002/jso.24023.
[51] Rutledge FN, Smith JP, Wharton JT, et al. Pelvic exenteration: analysis of 296 patients[J]. Am J Obstet Gynecol, 1977,129(8):881-892. DOI: 10.1016/0002-9378 (77)90521-x.
[52] Jimenez RE, Shoup M, Cohen AM, et al. Contemporary outcomes of total pelvic exenteration in the treatment of colorectal cancer[J]. Dis Colon Rectum, 2003,46(12):1619-1625. DOI: 10.1007/BF02660766.
[53] Khan O, Patsouras D, Ravindraanandan M, et al. Total Pelvic Exenteration for Locally Advanced and Recurrent Rectal Cancer: Urological Outcomes and Adverse Events[J]. Eur Urol Focus, 2021,7(3):638-643. DOI: 10.1016/j.euf.2020.06.008.
[54] Hagemans J, Voogt E, Rothbarth J, et al. Outcomes of urinary diversion after surgery for locally advanced or locally recurrent rectal cancer with complete cystectomy; ileal and colon conduit[J]. Eur J Surg Oncol, 2020,46(6):1160-1166. DOI: 10.1016/j.ejso.2020.02.021.
[55] Venchiarutti RL, Solomon MJ, Koh CE, et al. Pushing the boundaries of pelvic exenteration by maintaining survival at the cost of morbidity[J]. Br J Surg, 2019,106(10):1393- 1403. DOI: 10.1002/bjs.11203.
[56] Radwan RW, Jones HG, Rawat N, et al. Determinants of survival following pelvic exenteration for primary rectal cancer[J]. Br J Surg, 2015,102(10):1278-1284. DOI: 10. 1002/bjs.9841.
[57] Kaur M, Joniau S, D’hoore A, et al. Pelvic exenterations for gynecological malignancies: a study of 36 cases[J]. Int J Gynecol Cancer, 2012, 22(5): 889-896. DOI: 10.1097/IGC. 0b013e31824eb8cd.
[58] Sutton PA, Brown K, Ebrahimi N, et al. Long-term surgical complications following pelvic exenteration: operative management of the empty pelvis syndrome[J]. Colorectal Dis, 2022. DOI: 10.1111/codi.16238.
[59] Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer[J]. JAMA Oncol, 2019,5(8):1124-1131. DOI: 10.1001/jamaoncol.2019.0528.
[60] PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer[J]. Br J Surg, 2018, 105(6): 650-657. DOI: 10.1002/bjs.10734.
